NASDAQ: ALZN
Alzamend Neuro Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their ALZN stock forecasts and price targets.

Forecast return on equity

Is ALZN forecast to generate an efficient return?

Company
-152.78%
Industry
90.72%
Market
171.02%
ALZN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ALZN forecast to generate an efficient return on assets?

Company
-82.57%
Industry
27.38%
ALZN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ALZN earnings per share forecast

What is ALZN's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$2.65
Avg 2 year Forecast
-$3.10
Avg 3 year Forecast
-$0.88

ALZN revenue forecast

What is ALZN's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$32.8M

ALZN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ALZN$1.18N/AN/A
CANF$3.25$7.50+130.77%Strong Buy
FBLG$0.92$74.00+7,969.79%Strong Buy
SXTP$1.56$13.85+787.82%Buy
MTNB$0.76N/AN/A

Alzamend Neuro Stock Forecast FAQ

What is ALZN's earnings growth forecast for 2027-2029?

(NASDAQ: ALZN) Alzamend Neuro's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.72%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.38%.

Alzamend Neuro's earnings in 2026 is -$7,632,109.On average, 3 Wall Street analysts forecast ALZN's earnings for 2027 to be -$10,090,173, with the lowest ALZN earnings forecast at -$9,694,480, and the highest ALZN earnings forecast at -$10,386,943. On average, 3 Wall Street analysts forecast ALZN's earnings for 2028 to be -$11,797,741, with the lowest ALZN earnings forecast at -$11,335,084, and the highest ALZN earnings forecast at -$12,144,733.

In 2029, ALZN is forecast to generate -$3,337,519 in earnings, with the lowest earnings forecast at -$3,206,636 and the highest earnings forecast at -$3,435,681.

If you're new to stock investing, here's how to buy Alzamend Neuro stock.

What is ALZN's revenue growth forecast for 2027-2029?

(NASDAQ: ALZN) Alzamend Neuro's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.44%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.17%.

Alzamend Neuro's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast ALZN's revenue for 2027 to be $0, with the lowest ALZN revenue forecast at $0, and the highest ALZN revenue forecast at $0. On average, 3 Wall Street analysts forecast ALZN's revenue for 2028 to be $0, with the lowest ALZN revenue forecast at $0, and the highest ALZN revenue forecast at $0.

In 2029, ALZN is forecast to generate $124,905,842 in revenue, with the lowest revenue forecast at $120,005,336 and the highest revenue forecast at $128,577,417.

What is ALZN's forecast return on assets (ROA) for 2027-2029?

(NASDAQ: ALZN) forecast ROA is -82.57%, which is lower than the forecast US Biotechnology industry average of 27.38%.

What is ALZN's Earnings Per Share (EPS) forecast for 2027-2029?

(NASDAQ: ALZN) Alzamend Neuro's current Earnings Per Share (EPS) is -$4.18. On average, analysts forecast that ALZN's EPS will be -$2.65 for 2027, with the lowest EPS forecast at -$2.55, and the highest EPS forecast at -$2.73. On average, analysts forecast that ALZN's EPS will be -$3.10 for 2028, with the lowest EPS forecast at -$2.98, and the highest EPS forecast at -$3.19. In 2029, ALZN's EPS is forecast to hit -$0.88 (min: -$0.84, max: -$0.90).

What is ALZN's forecast return on equity (ROE) for 2027-2029?

(NASDAQ: ALZN) forecast ROE is -152.78%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.